Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Djokovic, Dusan ^a,b   Trindade, Alexandre ^a,b   Gigante, Joana ^a,b   Badenes, Marina ^a,b   Silva, Lilliana ^a,b   Liu, Ren ^c   Li, Xiuqing ^c   Gong, Ming ^c   Krasnoperov, Valery ^d   Gill, Parkash S ^c   Duarte, Antonio ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Vasgene Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; DELTA LIKE LIGAND 4; EPHRIN B2; EPHRIN B4; LECTIN; MEMBRANE PROTEIN; NOTCH RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DLL4 PROTEIN, MOUSE; EPHB4 PROTEIN, MOUSE; EPHRIN RECEPTOR B4; HYBRID PROTEIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; INSULINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; ENDOTHELIUM CELL; GENE THERAPY; GENETICS; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; TIME; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOTHELIAL CELLS; EPHRIN-B2; GENE THERAPY; INSULINOMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECEPTOR, EPHB4; RECEPTORS, NOTCH; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN;

EID: 78549253191     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-641     Document Type: Article

References (39)

1. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009, 7(1):21-33. 10.1111/j.1538-7836.2008.03203.x, 18983480.
2. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603. 10.1038/nrc2442, 2874834, 18650835.
3. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 2004, 101(45):15949-54. 10.1073/pnas.0407290101, 524697, 15520367.
4. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 2004, 18(20):2474-8. 10.1101/gad.1239004, 529534, 15466159.
5. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005, 65(19):8690-7. 10.1158/0008-5472.CAN-05-1208, 16204037.
6. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001, 69(2-3):135-44. 10.1046/j.1432-0436.2001.690207.x, 11798067.
7. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444(7122):1032-7. 10.1038/nature05355, 17183313.
8. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007, 109(11):4753-60. 10.1182/blood-2006-12-063933, 1885521, 17311993.
9. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006, 107(3):931-9. 10.1182/blood-2005-03-1000, 1895896, 16219802.
10. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 2007, 104(9):3219-24. 10.1073/pnas.0611206104, 1805530, 17296940.
11. Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, Eichmann A. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 2007, 104(9):3225-30. 10.1073/pnas.0611177104, 1805603, 17296941.
12. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444(7122):1083-7. 10.1038/nature05313, 17183323.
13. Gerety SS, Anderson DJ. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 2002, 129(6):1397-1410.
14. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999, 13(3):295-306. 10.1101/gad.13.3.295, 316426, 9990854.
15. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999, 4(3):403-414. 10.1016/S1097-2765(00)80342-1, 10518221.
16. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006, 107(6):2330-2338. 10.1182/blood-2005-04-1655, 1895726, 16322467.
17. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009, 113(1):254-263. 10.1182/blood-2008-02-140020, 2614637, 18836096.
18. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315(6015):115-122. 10.1038/315115a0, 2986015.
19. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284(5415):808-812. 10.1126/science.284.5415.808, 10221914.
20. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463(7282):E6-7. 10.1038/nature08751, 20147986.
21. Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 2010, 115(4):887-895. 10.1182/blood-2009-08-236745, 19965636.
22. Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, Koyanagi A, Yamaguchi N, Yagita H, Arai H. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 2009, 113(15):3631-3639. 10.1182/blood-2008-07-170381, 19218547.
23. Iso T, Maeno T, Oike Y, Yamazaki M, Doi H, Arai M, Kurabayashi M. Dll4-selective Notch signaling induces ephrinB2 gene expression in endothelial cells. Biochem Biophys Res Commun 2006, 341(3):708-14. 10.1016/j.bbrc.2006.01.020, 16430858.
24. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, Dupuy E. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006, 66(17):8501-10. 10.1158/0008-5472.CAN-05-4226, 16951162.
25. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010, 465(7297):487-491. 10.1038/nature08995, 20445540.
26. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465(7297):483-486. 10.1038/nature09002, 20445537.
27. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 2004, 14(3):379-383. 10.1016/j.conb.2004.05.010, 15194119.
28. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003, 26:565-597. 10.1146/annurev.neuro.26.041002.131334, 12730322.
29. Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Klonjkowski B, Berrou E, Mericskay M, Li Z, Tournier-Lasserve E, Gridley T, Joutel A. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004, 18(22):2730-2735. 10.1101/gad.308904, 528893, 15545631.
30. Liu H, Kennard S, Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ Res 2009, 104(4):466-475. 10.1161/CIRCRESAHA.108.184846, 2747310, 19150886.
31. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005, 97(6):512-523. 10.1161/01.RES.0000182903.16652.d7, 16166562.
32. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295. 154450, 12727920.
33. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003, 112(8):1142-1151. 213487, 14561699.
34. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001, 61(4):1464-1468.
35. Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, Dewhirst MW, Sankar S. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 2004, 59:51-71. 10.1210/rp.59.1.51, 14749497.
36. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376(6535):70-74. 10.1038/376070a0, 7596437.
37. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, Shani M, Zicha D, Adams RH. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 2006, 124(1):161-173. 10.1016/j.cell.2005.10.034, 16413489.
38. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Grone HJ, Hammerling GJ, Arnold B, Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453(7193):410-414. 10.1038/nature06868, 18418378.
39. Jin Y, An X, Ye Z, Cully B, Wu J, Li J. RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J Biol Chem 2009, 284(35):23436-23443. 10.1074/jbc.M109.032664, 2749117, 19564336.